Skip to main content
Log in

Antibody evolution beyond Nature

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: An approach for constructing scFv fragments that display germline CDR combinations not accessible to nature.
Figure 2

References

  1. http://www.phrma.org/newmedicines/

  2. Johnson, T.A. & Press, O.W. Ann. Hematol. 4, 175–182 (2000).

    Article  Google Scholar 

  3. McLaughlin, P. et al. J. Clin. Oncol. 16, 2825–2833 (1998).

    Article  CAS  Google Scholar 

  4. Chang, T.W. Nat. Biotechnol. 18, 157–162 (2000).

    Article  CAS  Google Scholar 

  5. Söderlind, E., Carlsson, R., Borrebaeck, C.A.K & Ohlin M. Comb. Chem. High Throughput Screen. 4, 409–416 (2001).

    Article  Google Scholar 

  6. Fishwild, D.M. et al. Nat. Biotechnol. 14, 845–851 (1996).

    Article  CAS  Google Scholar 

  7. Soderlind, E. et al. Nat. Biotechnol. 8, 852–856 (2000).

    Article  Google Scholar 

  8. Knappik, A. et al. J. Mol. Biol. 296, 57–86 (2000).

    Article  CAS  Google Scholar 

  9. Sblattero, D. & Bradbury, A. Nat. Biotechnol. 18, 75–80 (2000).

    Article  CAS  Google Scholar 

  10. Jirholt, P., Borrebaeck, C.A.K. & Ohlin, M. J. Mol. Biol. 318, 407–416 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borrebaeck, C., Ohlin, M. Antibody evolution beyond Nature. Nat Biotechnol 20, 1189–1190 (2002). https://doi.org/10.1038/nbt1202-1189

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1202-1189

  • Springer Nature America, Inc.

This article is cited by

Navigation